MVNE:TASEMivne Real Estate (K.D) Ltd. Analysis
Data as of 2026-03-15 - not real-time
ILA 1,405.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at 1,405, just above the 20‑day SMA of 1,400 and comfortably above the 200‑day SMA of 1,307, suggesting a slight upward bias while still below the 50‑day SMA of 1,482, indicating short‑term resistance. RSI sits at 46.9, placing the market in a neutral zone without clear overbought or oversold pressure. The MACD histogram is positive (7.57) with a bullish signal line crossover, reinforcing a modest upside momentum. Volatility over the past 30 days is elevated at 33%, but the computed beta of 0.03 points to very low systematic risk. Liquidity appears adequate with stable volume and a market cap of roughly 10 bn ILA. On the fundamentals side, the trailing P/E of 15 is well below the industry average of 32, hinting at earnings‑based undervaluation, yet the price‑to‑book ratio of 116 is astronomically high, reflecting a severe overvaluation on a balance‑sheet basis. The company carries a massive debt load of 8.73 bn ILA, pushing the debt‑to‑equity ratio to 100%, which raises concerns about financial flexibility. Despite a 9.9% revenue contraction, margins remain strong (gross 60%, operating 57%) and cash flow is positive, supporting the current 1.77% dividend yield with a modest 17.5% payout. Overall, the technical picture is cautiously optimistic, but the fundamental stresses—high leverage and an inflated book multiple—temper enthusiasm.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD histogram with signal crossover
- Price above 20‑day SMA and near support level
- Sustainable dividend yield of 1.77%
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- High price‑to‑book ratio indicating overvaluation
- Elevated debt‑to‑equity ratio limiting financial flexibility
- Neutral RSI and mixed technical signals
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Persistent revenue decline and high leverage
- Extreme PB multiple suggesting long‑term price correction
- Potential regulatory and geographic headwinds across multiple markets
Key Metrics & Analysis
Financial Health
Revenue Growth-9.90%
Profit Margin46.47%
P/E Ratio15.1
ROE8.09%
ROA2.43%
Debt/Equity100.05
P/B Ratio116.1
Op. Cash FlowILA785.4M
Free Cash FlowILA359.2M
Industry P/E32.5
Technical Analysis
TrendNeutral
RSI46.9
SupportILA 1,253.00
ResistanceILA 1,529.00
MA 20ILA 1,400.05
MA 50ILA 1,482.36
MA 200ILA 1,306.59
MACDBullish
VolumeStable
Fear & Greed Index72.88
Valuation
GradeOvervalued
TypeValue
Dividend Yield1.77%
Risk Assessment
Beta0.03
Volatility33.27%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.